Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

August 24, 2027

Study Completion Date

August 24, 2031

Conditions
Large B-cell Lymphoma
Interventions
GENETIC

cemacabtagene ansegedleucel

An allogeneic CAR T cell therapy targeting CD19

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

DEVICE

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL.

Trial Locations (53)

10032

RECRUITING

Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

19713

RECRUITING

Medical Oncology Hematology Consultants, Newark

20007

RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

20817

RECRUITING

The Center for Cancer and Blood Disorders, Bethesda

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

22903

RECRUITING

University of Virginia, Charlottesville

23502

RECRUITING

Virginia Oncology Associates - Norfolk, Norfolk

27705

RECRUITING

Duke Blood Cancer Center, Durham

28204

RECRUITING

Novant Health Cancer Institute- Hematology, Charlotte

30912

RECRUITING

Augusta University Georgia Cancer Center, Augusta

32804

RECRUITING

Advent Health Cancer Institute, Orlando

33176

RECRUITING

Miami Cancer Institute at Baptist Health, Inc., Miami

33612

RECRUITING

Moffitt Cancer Center, Tampa

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

40202

RECRUITING

University of Louisville Health Brown Cancer Center, Louisville

40207

RECRUITING

Norton Cancer Institute, Louisville

40536

RECRUITING

University of Kentucky Medical Center, Lexington

44195

RECRUITING

Cleveland Clinic, Cleveland

45236

RECRUITING

Oncology Hematology Care - Kenwood, Cincinnati

45267

RECRUITING

University of Cincinnati Medical Center, Cincinnati

46237

RECRUITING

Indiana Blood and Marrow Transplantation, Indianapolis

60612

RECRUITING

Rush University Medical Center, Chicago

63110

RECRUITING

Washington University School of Medicine - Siteman Cancer Center, St Louis

65212

RECRUITING

University of Missouri - Ellis Fischel Cancer Center, Columbia

66205

RECRUITING

The University of Kansas Hospital, Kansas City

75246

RECRUITING

Texas Oncology - Dallas Fort Worth, Dallas

75702

RECRUITING

Texas Oncology - Tyler, Tyler

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

Texas Transplant Institute, San Antonio

78705

RECRUITING

Texas Oncology - Central South, Austin

80218

RECRUITING

Rocky Mountain Cancer Centers, Denver

84112

RECRUITING

Huntsman Cancer Institute, University of Utah, Salt Lake City

84142

RECRUITING

Intermountain Health LDS Hospital, Salt Lake City

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

90095

RECRUITING

University of California, Los Angeles, Los Angeles

91010

RECRUITING

City of Hope, Duarte

91817

RECRUITING

University of California, Davis Comprehensive Cancer Center, Sacramento

92037

RECRUITING

University of California, San Diego, San Diego

94143

RECRUITING

University of California, San Francisco, San Francisco

94704

RECRUITING

Alta Bates Summit Medical Center, Berkeley

97239

RECRUITING

Oregon Health and Science University, Portland

97401

RECRUITING

Oncology Associates of Oregon, Eugene

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

08816

RECRUITING

Astera Cancer Care, East Brunswick

07601

RECRUITING

John Theurer Cancer Center, Hackensack

08901

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

B3H 2Y9

RECRUITING

Queen Elizabeth II Health Sciences Centre, Halifax

M5G 1Z5

RECRUITING

Princess Margaret Cancer Centre - University Health Network, Toronto

G1R 2J6

RECRUITING

Hopital de'L'Enfant-Jesus, Québec

Sponsors
All Listed Sponsors
collaborator

Foresight Diagnostics, Inc.

UNKNOWN

lead

Allogene Therapeutics

INDUSTRY

NCT06500273 - Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Biotech Hunter | Biotech Hunter